LIVIVO - Search results -

Search results

Result 1 - 10 of total 13

Search options

Article: Treatment of COVID-19 in Patients With Sarcoidosis.

Kondle, Shreya / Hou, Titus / Manansala, Michael / Ascoli, Christian / Novak, Richard M / Sweiss, Nadera

2021 Volume 8, Page(s) 689539

Abstract: Recent case reports and studies on treating COVID-19 in patients with chronic sarcoidosis describe ... management algorithm for sarcoidosis patients who develop COVID-19. We emphasize a need for exchange ... of information regarding management of COVID-19 in the setting of sarcoidosis to further improve treatment ...

Abstract	Recent case reports and studies on treating COVID-19 in patients with chronic sarcoidosis describe different treatment modalities ranging from glucocorticoids to biologic medications. This review article summarizes seven case series and reports totaling 46 patients. While one case report suggested that sarcoidosis medications such as glucocorticoids may lengthen the COVID-19 disease course, another study with a larger registry suggests they do not. More studies are needed to elucidate an improvement in outcomes. It is possible that addition of TNF-alpha inhibitors at COVID-19 diagnosis decreases hospitalization rate. Overall, it is difficult to make firm conclusions regarding treatment given the heterogeneity of treatment modalities in the current literature. Our summarized findings are outlined with the opinions of sarcoidosis, pulmonary, and infectious disease experts in a flow chart that provides clinicians with our proposed management algorithm for sarcoidosis patients who develop COVID-19. We emphasize a need for exchange of information regarding management of COVID-19 in the setting of sarcoidosis to further improve treatment in this vulnerable population of patients.
Language	English
Publishing date	2021-07-16
Publishing country	Switzerland
Document type	Journal Article ; Review
ZDB-ID	2775999-4
ISSN	2296-858X
ISSN	2296-858X
DOI	10.3389/fmed.2021.689539
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Article ; Online: Treatment of COVID-19 in Patients With Sarcoidosis

Shreya Kondle / Titus Hou / Michael Manansala / Christian Ascoli / Richard M. Novak / Nadera Sweiss

Frontiers in Medicine, Vol

2021 Volume 8

Abstract	Recent case reports and studies on treating COVID-19 in patients with chronic sarcoidosis describe different treatment modalities ranging from glucocorticoids to biologic medications. This review article summarizes seven case series and reports totaling 46 patients. While one case report suggested that sarcoidosis medications such as glucocorticoids may lengthen the COVID-19 disease course, another study with a larger registry suggests they do not. More studies are needed to elucidate an improvement in outcomes. It is possible that addition of TNF-alpha inhibitors at COVID-19 diagnosis decreases hospitalization rate. Overall, it is difficult to make firm conclusions regarding treatment given the heterogeneity of treatment modalities in the current literature. Our summarized findings are outlined with the opinions of sarcoidosis, pulmonary, and infectious disease experts in a flow chart that provides clinicians with our proposed management algorithm for sarcoidosis patients who develop COVID-19. We emphasize a need for exchange of information regarding management of COVID-19 in the setting of sarcoidosis to further improve treatment in this vulnerable population of patients.
Keywords	COVID-19 ; sarcoidosis ; SARS-CoV-2 ; management ; treatment ; immunocompromised ; Medicine (General) ; R5-920
Subject code	610
Language	English
Publishing date	2021-07-01T00:00:00Z
Publisher	Frontiers Media S.A.
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article: [Diagnostic and treatment difficulties in kidney damage in the patient with generalized sarcoidosis during COVID-19. Case report].

Lebedeva, M V / Chebotareva, N V / Beketov, V D

Terapevticheskii arkhiv

2022 Volume 94, Issue 6, Page(s) 769–771

Abstract: ... of progressive kidney damage in a patient with sarcoidosis who has undergone a new coronavirus infection ... of the sarcoidosis process, restoration of kidney function. ...

Abstract	The presented clinical observation reflects the difficulties of differential diagnosis of progressive kidney damage in a patient with sarcoidosis who has undergone a new coronavirus infection. The differential circle included interstitial nephritis as an exacerbation of the underlying disease, acute drug-induced kidney injury, acute glomerulonephritis. Nephrobiopsy confirmed the diagnosis of acute sarcoid tubulointerstitial nephritis with acute tubular necrosis. Timely administration of corticosteroids led to the control of the sarcoidosis process, restoration of kidney function.
MeSH term(s)	Humans ; COVID-19/diagnosis ; Nephritis, Interstitial/diagnosis ; Nephritis, Interstitial/drug therapy ; Nephritis, Interstitial/etiology ; Sarcoidosis/complications ; Sarcoidosis/diagnosis ; Sarcoidosis/drug therapy ; Adrenal Cortex Hormones/therapeutic use ; Kidney/pathology
Chemical Substances	Adrenal Cortex Hormones
Language	Russian
Publishing date	2022-08-04
Publishing country	Russia (Federation)
Document type	Case Reports ; English Abstract ; Journal Article
ZDB-ID	40718-5
ISSN	2309-5342 ; 0040-3660
ISSN (online)	2309-5342
ISSN	0040-3660
DOI	10.26442/00403660.2022.06.201566
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 79: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Diagnostic and treatment difficulties in kidney damage in the patient with generalized sarcoidosis during COVID-19. Case report

Marina V. Lebedeva / Natalia V. Chebotareva / Vladimir D. Beketov

Терапевтический архив, Vol 94, Iss 6, Pp 769-

2022 Volume 771

Abstract: ... of progressive kidney damage in a patient with sarcoidosis who has undergone a new coronavirus infection ... of the sarcoidosis process, restoration of kidney function. ...

Abstract	The presented clinical observation reflects the difficulties of differential diagnosis of progressive kidney damage in a patient with sarcoidosis who has undergone a new coronavirus infection. The differential circle included interstitial nephritis as an exacerbation of the underlying disease, acute drug-induced kidney injury, acute glomerulonephritis. Nephrobiopsy confirmed the diagnosis of acute sarcoid tubulointerstitial nephritis with acute tubular necrosis. Timely administration of corticosteroids led to the control of the sarcoidosis process, restoration of kidney function.
Keywords	sarcoidosis tubulo-interstitial nephritis ; generalized sarcoidosis ; new coronavirus infection ; Medicine ; R
Language	Russian
Publishing date	2022-08-01T00:00:00Z
Publisher	"Consilium Medicum" Publishing house
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: COVID-19 in Patient with Sarcoidosis Receiving Long-Term Hydroxychloroquine Treatment, France, 2020.

Bénézit, François / Le Bot, Audrey / Jouneau, Stéphane / Lemaître, Florian / Pronier, Charlotte / Lentz, Pierre-Axel / Patrat-Delon, Solène / Revest, Matthieu / Thibault, Vincent / Tattevin, Pierre

Emerging infectious diseases

2020 Volume 26, Issue 10, Page(s) 2513–2515

Abstract: ... of COVID-19 in a patient with sarcoidosis who was receiving long-term hydroxychloroquine treatment and ... postexposure prophylaxis for coronavirus disease (COVID-19) and as a possible COVID-19 curative treatment. We report a case ... contracted COVID-19 despite adequate plasma concentrations. ...

Abstract	Because of in vitro studies, hydroxychloroquine has been evaluated as a preexposure or postexposure prophylaxis for coronavirus disease (COVID-19) and as a possible COVID-19 curative treatment. We report a case of COVID-19 in a patient with sarcoidosis who was receiving long-term hydroxychloroquine treatment and contracted COVID-19 despite adequate plasma concentrations.
MeSH term(s)	Adult ; Antimalarials/blood ; Antimalarials/therapeutic use ; COVID-19 ; Coronavirus Infections/complications ; Coronavirus Infections/diagnosis ; France ; Humans ; Hydroxychloroquine/blood ; Hydroxychloroquine/therapeutic use ; Male ; Pandemics ; Pneumonia, Viral/complications ; Pneumonia, Viral/diagnosis ; Sarcoidosis, Pulmonary/complications ; Sarcoidosis, Pulmonary/drug therapy ; Time Factors ; Tomography, X-Ray Computed
Chemical Substances	Antimalarials ; Hydroxychloroquine (4QWG6N8QKH)
Keywords	covid19
Language	English
Publishing date	2020-07-01
Publishing country	United States
Document type	Case Reports ; Letter
ZDB-ID	1380686-5
ISSN	1080-6059 ; 1080-6040
ISSN (online)	1080-6059
ISSN	1080-6040
DOI	10.3201/eid2610.201816
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 4778: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: COVID-19 in Patient with Sarcoidosis Receiving Long-Term Hydroxychloroquine Treatment, France, 2020

François Bénézit / Audrey Le Bot / Stéphane Jouneau / Florian Lemaître / Charlotte Pronier / Pierre-Axel Lentz / Solène Patrat-Delon / Matthieu Revest / Vincent Thibault / Pierre Tattevin

Emerging Infectious Diseases, Vol 26, Iss 10, Pp 2513-

2020 Volume 2515

Abstract	Because of in vitro studies, hydroxychloroquine has been evaluated as a preexposure or postexposure prophylaxis for coronavirus disease (COVID-19) and as a possible COVID-19 curative treatment. We report a case of COVID-19 in a patient with sarcoidosis who was receiving long-term hydroxychloroquine treatment and contracted COVID-19 despite adequate plasma concentrations.
Keywords	COVID-19 ; 2019 novel coronavirus disease ; hydroxychloroquine ; plasma concentration ; sarcoidosis ; France ; Medicine ; R ; Infectious and parasitic diseases ; RC109-216 ; covid19
Language	English
Publishing date	2020-10-01T00:00:00Z
Publisher	Centers for Disease Control and Prevention
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article: COVID-19 in Patient with Sarcoidosis Receiving Long-Term Hydroxychloroquine Treatment, France, 2020

Emerg Infect Dis

Abstract	Because of in vitro studies, hydroxychloroquine has been evaluated as a preexposure or postexposure prophylaxis for coronavirus disease (COVID-19) and as a possible COVID-19 curative treatment. We report a case of COVID-19 in a patient with sarcoidosis who was receiving long-term hydroxychloroquine treatment and contracted COVID-19 despite adequate plasma concentrations.
Keywords	covid19
Publisher	WHO
Document type	Article
Note	WHO #Covidence: #623269
Database	COVID19

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾

Article ; Online: Results From a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Repository Corticotropin Injection for the Treatment of Pulmonary Sarcoidosis.

Mirsaeidi, Mehdi / Baughman, Robert P / Sahoo, Debasis / Tarau, Eva

Pulmonary therapy

2023 Volume 9, Issue 2, Page(s) 237–253

Abstract: ... pulmonary function tests, chest imaging, patient-reported outcomes, and a novel sarcoidosis treatment score (STS). Safety ... with RCI compared to placebo in patients receiving standard-of-care therapy for pulmonary sarcoidosis ... and imaging. The study was terminated early due to low enrollment caused by the COVID-19 pandemic ...

Abstract	Introduction: Long-term treatment of pulmonary sarcoidosis with glucocorticoids has been associated with toxicity and other adverse events, highlighting the need for alternative therapies. The goal of this study was to evaluate the efficacy and safety of repository corticotropin injection (RCI, Acthar Methods: In this multicenter, randomized, placebo-controlled trial, subjects received subcutaneous RCI (80 U) twice weekly or matching placebo through 24 weeks in a double-blind treatment phase, followed by an optional 24-week open-label extension. Efficacy was measured by glucocorticoid tapering, pulmonary function tests, chest imaging, patient-reported outcomes, and a novel sarcoidosis treatment score (STS). Safety was assessed by adverse events, physical examinations, vital signs, clinical laboratory abnormalities, and imaging. The study was terminated early due to low enrollment caused by the COVID-19 pandemic, thereby precluding statistical analysis. Results: Fifty-five subjects were randomized to receive either RCI (n = 27) or placebo (n = 28). Mean STS at week 24 showed greater improvement with RCI (1.4) compared with placebo (0.7). At week 48, those who remained on RCI had an STS of 1.8 compared with 0.9 in those who switched from placebo to RCI. More subjects in the RCI group discontinued glucocorticoids at week 24 compared to the placebo group. Glucocorticoid discontinuation was comparable at week 48 for those who switched from placebo to RCI and those who continued RCI. Similar trends in favor of RCI over placebo were observed with the other efficacy endpoints. No new or unexpected safety signals were identified. Conclusions: RCI was safe and well tolerated, with trends in efficacy data suggesting greater improvement with RCI compared to placebo in patients receiving standard-of-care therapy for pulmonary sarcoidosis. The study also provided validation of efficacy endpoints that may be used in larger trials for pulmonary sarcoidosis. Trial registration: ClinicalTrials.gov identifier: NCT03320070.
Language	English
Publishing date	2023-04-19
Publishing country	United States
Document type	Journal Article
ISSN	2364-1746
ISSN (online)	2364-1746
DOI	10.1007/s41030-023-00222-2
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Association between pre-existing respiratory disease and its treatment, and severe COVID-19: a population cohort study.

Aveyard, Paul / Gao, Min / Lindson, Nicola / Hartmann-Boyce, Jamie / Watkinson, Peter / Young, Duncan / Coupland, Carol A C / Tan, Pui San / Clift, Ashley K / Harrison, David / Gould, Doug W / Pavord, Ian D / Hippisley-Cox, Julia

The Lancet. Respiratory medicine

2021 Volume 9, Issue 8, Page(s) 909–923

Abstract: ... in patients hospitalised with COVID-19 was lower than its prevalence in the general population. The aim ... deaths for COVID-19. All patients aged 20 years and older who were registered with one of the 1205 ... the risk of contracting severe COVID-19.: Methods: In this population cohort study, records from 1205 ...

Abstract	Background: Previous studies suggested that the prevalence of chronic respiratory disease in patients hospitalised with COVID-19 was lower than its prevalence in the general population. The aim of this study was to assess whether chronic lung disease or use of inhaled corticosteroids (ICS) affects the risk of contracting severe COVID-19. Methods: In this population cohort study, records from 1205 general practices in England that contribute to the QResearch database were linked to Public Health England's database of SARS-CoV-2 testing and English hospital admissions, intensive care unit (ICU) admissions, and deaths for COVID-19. All patients aged 20 years and older who were registered with one of the 1205 general practices on Jan 24, 2020, were included in this study. With Cox regression, we examined the risks of COVID-19-related hospitalisation, admission to ICU, and death in relation to respiratory disease and use of ICS, adjusting for demographic and socioeconomic status and comorbidities associated with severe COVID-19. Findings: Between Jan 24 and April 30, 2020, 8 256 161 people were included in the cohort and observed, of whom 14 479 (0·2%) were admitted to hospital with COVID-19, 1542 (<0·1%) were admitted to ICU, and 5956 (0·1%) died. People with some respiratory diseases were at an increased risk of hospitalisation (chronic obstructive pulmonary disease [COPD] hazard ratio [HR] 1·54 [95% CI 1·45-1·63], asthma 1·18 [1·13-1·24], severe asthma 1·29 [1·22-1·37; people on three or more current asthma medications], bronchiectasis 1·34 [1·20-1·50], sarcoidosis 1·36 [1·10-1·68], extrinsic allergic alveolitis 1·35 [0·82-2·21], idiopathic pulmonary fibrosis 1·59 [1·30-1·95], other interstitial lung disease 1·66 [1·30-2·12], and lung cancer 2·24 [1·89-2·65]) and death (COPD 1·54 [1·42-1·67], asthma 0·99 [0·91-1·07], severe asthma 1·08 [0·98-1·19], bronchiectasis 1·12 [0·94-1·33], sarcoidosis 1·41 [0·99-1·99), extrinsic allergic alveolitis 1·56 [0·78-3·13], idiopathic pulmonary fibrosis 1·47 [1·12-1·92], other interstitial lung disease 2·05 [1·49-2·81], and lung cancer 1·77 [1·37-2·29]) due to COVID-19 compared with those without these diseases. Admission to ICU was rare, but the HR for people with asthma was 1·08 (0·93-1·25) and severe asthma was 1·30 (1·08-1·58). In a post-hoc analysis, relative risks of severe COVID-19 in people with respiratory disease were similar before and after shielding was introduced on March 23, 2020. In another post-hoc analysis, people with two or more prescriptions for ICS in the 150 days before study start were at a slightly higher risk of severe COVID-19 compared with all other individuals (ie, no or one ICS prescription): HR 1·13 (1·03-1·23) for hospitalisation, 1·63 (1·18-2·24) for ICU admission, and 1·15 (1·01-1·31) for death. Interpretation: The risk of severe COVID-19 in people with asthma is relatively small. People with COPD and interstitial lung disease appear to have a modestly increased risk of severe disease, but their risk of death from COVID-19 at the height of the epidemic was mostly far lower than the ordinary risk of death from any cause. Use of inhaled steroids might be associated with a modestly increased risk of severe COVID-19. Funding: National Institute for Health Research Oxford Biomedical Research Centre and the Wellcome Trust.
MeSH term(s)	Administration, Inhalation ; Adrenal Cortex Hormones/administration & dosage ; Adrenal Cortex Hormones/adverse effects ; COVID-19/diagnosis ; COVID-19/epidemiology ; COVID-19/physiopathology ; COVID-19 Testing ; Comorbidity ; England/epidemiology ; Female ; Hospitalization/statistics & numerical data ; Humans ; Intensive Care Units/statistics & numerical data ; Male ; Middle Aged ; Mortality ; Pulmonary Disease, Chronic Obstructive/diagnosis ; Pulmonary Disease, Chronic Obstructive/drug therapy ; Pulmonary Disease, Chronic Obstructive/epidemiology ; Risk Assessment ; SARS-CoV-2/isolation & purification ; Social Class
Chemical Substances	Adrenal Cortex Hormones
Language	English
Publishing date	2021-04-01
Publishing country	England
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2686754-0
ISSN	2213-2619 ; 2213-2600
ISSN (online)	2213-2619
ISSN	2213-2600
DOI	10.1016/S2213-2600(21)00095-3
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 7041: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Doxycycline treatment of high-risk COVID-19-positive patients with comorbid pulmonary disease.

Yates, Paul A / Newman, Steven A / Oshry, Lauren J / Glassman, Robert H / Leone, Ashton M / Reichel, Elias

Therapeutic advances in respiratory disease

2020 Volume 14, Page(s) 1753466620951053

Abstract: ... systemic response to SARS-CoV-2. We present a series of four high-risk, symptomatic, COVID-19 ... Infection with novel SARS-CoV-2 carries significant morbidity and mortality in patients ... established medications that may have antiviral activity is a possible approach for treatment of earlier-stage ...

Abstract	Infection with novel SARS-CoV-2 carries significant morbidity and mortality in patients with pulmonary compromise, such as lung cancer, autoimmune disease, and pneumonia. For early stages of mild to moderate disease, care is entirely supportive.Antiviral drugs such as remdesivir may be of some benefit but are reserved for severe cases given limited availability and potential toxicity. Repurposing of safer, established medications that may have antiviral activity is a possible approach for treatment of earlier-stage disease. Tetracycline and its derivatives (e.g. doxycycline and minocycline) are nontraditional antibiotics with a well-established safety profile, potential efficacy against viral pathogens such as dengue fever and chikungunya, and may regulate pathways important in initial infection, replication, and systemic response to SARS-CoV-2. We present a series of four high-risk, symptomatic, COVID-19
MeSH term(s)	Adenocarcinoma of Lung/complications ; Adenocarcinoma of Lung/diagnosis ; Adenocarcinoma of Lung/therapy ; Adult ; Aged ; Aged, 80 and over ; COVID-19 ; Comorbidity ; Coronavirus Infections/complications ; Coronavirus Infections/diagnosis ; Coronavirus Infections/drug therapy ; Doxycycline/administration & dosage ; Female ; Follow-Up Studies ; Humans ; Male ; Middle Aged ; Multimorbidity ; Pandemics ; Pneumonia, Viral/complications ; Pneumonia, Viral/diagnosis ; Pneumonia, Viral/drug therapy ; Pulmonary Disease, Chronic Obstructive/complications ; Pulmonary Disease, Chronic Obstructive/diagnosis ; Pulmonary Disease, Chronic Obstructive/therapy ; Risk Assessment ; Sampling Studies ; Sarcoidosis, Pulmonary/complications ; Sarcoidosis, Pulmonary/diagnosis ; Sarcoidosis, Pulmonary/therapy ; Treatment Outcome
Chemical Substances	Doxycycline (N12000U13O)
Keywords	covid19
Language	English
Publishing date	2020-09-01
Publishing country	England
Document type	Journal Article ; Review
ZDB-ID	2476459-0
ISSN	1753-4666 ; 1753-4658
ISSN (online)	1753-4666
ISSN	1753-4658
DOI	10.1177/1753466620951053
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 6753: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

Inter-library loan at ZB MED

Kategorien

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito